63rd ASH Annual Meeting and Exposition
December 11-14, 2021
  • T/NK Cell Lymphoma Frontline Clinical Trials
  • Hodgkin Lymphoma Clinical Trials
  • T/NK Cell Lymphoma Relapsed Therapy
  • Hodgkin Lymphoma Clinical Outcomes Data

624. Hodgkin Lymphomas and T/NK cell Lymphomas: T/NK Cell Lymphoma Frontline Clinical Trials


Alex F. Herrera, Jasmine Zain, Kerry J. Savage, et al.

The authors conclude that in patients with mostly non-ALCL CD30 expressing PTCL, CHEP-BV (+/- ASCT) followed by BV consolidation was tolerable as well as effective.



Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Annalisa Chiappella, Cristiana Carniti, Alessandro Re, et al.

The study data showed that the addition of romidepsin to CHOEP did not improve the prognosis in newly diagnosed PTCLs for which HSCT is indicated.



Steven M. Horwitz, Kerry J. Savage, Tim Illidge, et al.

In this large prospective dataset of patients with PTCL, the 5 year study results show a generally consistent benefit of A + CHP over CHOP in all subgroups and for the ITT population. In addition, ECHELON-2 has redefined the efficacy outcomes for this population. It thus provides important benchmark data for future studies.



David Sibon, Sherine Khater, Julie Bruneau, et al.

BV-CHP was well tolerated in this first prospective phase 2 study dedicated to EATL. There were high response rates observed. As a result, the majority of the patients could be transplanted. The authors of the study conclude that the novel therapeutic approach shows promising efficacy compared to historical controls.


137 ASH denotes this abstract as clinically relevant  

Gao Yan, Yujing Zhang, Xiaoxiao Wang, et al.

For the first time in newly diagnosed ENKTL, effective antitumor activity was observed with Sintilimab plus Chidamid. The toxicities were manageable. The authors conclude that this could be a promising chemotherapy-free induction therapy for this population. In particular for patients in the early stages.


138 ASH denotes this abstract as clinically relevant  

Jia Ruan, Alison J. Moskowitz, Neha Mehta-Shah, et al.

Oral azacitidine (CC486) priming in combination with CHOP as initial therapy is safe and effective. It leads to sustained remission in the PTCL-TFH subtype. Epigenetic priming with azacitidine appears to inhibit the proliferation of TFH lymphoma cells. This suggests a potentially synergistic mechanism of action with chemotherapy.

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Trials

229 ASH denotes this abstract as clinically relevant

Locke J. Bryan, Carla Casulo,  Pamela Allen, et al.

Pembrolizumab plus ICE chemotherapy leads to a high CMR rate (assessed by PET / CT). The regime is well tolerated. After the transplant, the patients had excellent PFS and OS.



Veronika Bachanova, Livia Hegerova, Qing Cao, et al.

Patients with R / R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: ruxolitinib plus nivolumab leads to encouragingly high remission rates and sustained responses. The therapy is well tolerated.


231 ASH denotes this abstract as clinically relevant

Pamela Allen, Qing C Chen, Xinyan Lu, et al.

The sequential pembrolizumab and AVD chemotherapy remain a highly effective strategy after prolonged observation: High response rates were observed for all PD-L1 / PD-L2 levels and 100 percent of the patients remained alive without relapse, suggesting that response to PD-1 blockade in previously untreated cHL may occur even in low levels of PD-L expression.


232 ASH denotes this abstract as clinically relevant

Julien Lazarovici, Sandy Amorim, Krimo Bouabdallah, et al.

The results in elderly, frail patients with cHL suggest that nivolumab-based therapy is active in a subgroup of patients in this setting.


233 ASH denotes this abstract as clinically relevant

Ryan C. Lynch, Chaitra S. Ujjani, Christina Poh, et al.

The results of treatment with pembrolizumab + AVD without PD-1 lead-in show: This is a safe and effective therapy for Frontline HL. PET2 + following APVD does not seem to have a high risk of disease relapse.



Alex F. Herrera, Lu Chen, L. Elizabeth Budde, et al.

Pembrolizumab and vorinostat led to a high ORR and CR rate in patients with anti-PD1 naive/sensitive RR-HL. The combination was tolerated and most patients with anti-PD1 refractory RR-HL had an objective response. This also applies to patients who progressed during prior PD1 blockade.

624. Hodgkin Lymphomas and T/NK cell Lymphomas: T/NK Cell Lymphoma Relapsed Therapy


Steven M. Horwitz, Anastasia Nikitina, Nikita Kotlov, et al.

DR is highly active at R / R PTCL with an ORR of 58 percent and a CR of 42 percent. In addition, the tolerable DR provided an adequate response to allow frequent bridging to ASCT. In contrast to D alone, DR caused lower rates of transaminitis and had higher rates of CR. TET2 mutations and greater involvement of B cells predicted a response. TP53 mutations were only seen in NR. Biomarker-driven patient selection could further improve the ORR to DR.



Krimo Bouabdallah, Raphaëlle Aubrais, Loïc Chartier, et al.

The results of BBV in the treatment of R / R PTCL show a high response rate, a long DoR in responding patients and a very good outcome. Patients in CR eligible for transplant have the best outcome. Thus, in these high-risk lymphomas with limited treatment options, this combination is a good candidate for salvage therapy prior to transplant consolidation.



Thomas E. Witzig, Lubomir Sokol, Won Seog Kim, et al.

Tipifarnib has shown very encouraging efficacy in patients with CXCL12-expressing subtypes of PTCL (AITL and PTCL-CXCL12 +). The data show a tolerable safety profile.



Steven M. Horwitz, Tatyana A. Feldman, Jing C. Ye, et al.

A complete and sustained response to cerdulatinib has been observed in patients with the AITL / TFH subtype. This also applies to patients with repeated relapses and / or who were refractory to their last treatment. The substance has acceptable tolerability and clinical activity in PTCL. The benefit-risk profile appears to be favorable in this population. Exception: the PTCL-NOS subgroup, in which no response was observed. This subtype-specific activity motivates the identification of biomarkers in order to optimize patient selection.



Bradley M. Haverkos, Onder Alpdogan, Robert Baiocchi, et al.

In patients with R/R-EBV + lymphomas, particularly refractory T/NK-NHL, a heterogeneous group of aggressive lymphomas with a dismal outcome, Nstat plus VGCV showed promising efficacy with several lasting responses. The combination has a manageable toxicity profile and is well tolerated.


624 ASH denotes this abstract as clinically relevant

Henry S. Ngu, Stephen Parkin, David W. Scott, et al.

According to the authors, the results in the ITT R / R PTCLs are suboptimal: only about 1/3 of the patients have long-term survival. But if they receive an SCT, then more than half are still alive after 5 years. A third line of therapy can be a successful bridge to SCT. Then new active ingredients should be considered. Despite more refractory patients, the results with allo-SCT are encouraging

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Outcomes Data

877 ASH denotes this abstract as clinically relevant

Anna Santarsieri, Katherine Sturgess, Pauline Brice, et al.

Even if, according to the authors, this is a retrospective study, replacing procarbazine with dacarbazine probably does not limit the efficacy of eBPP and could have some toxicity benefits. Despite the clear preference to offer this regimen in advanced high-risk stages: With a median follow-up time of almost 2 years with eBPDac, the study authors observed a similar PFS and OS compared to HD18. However, survival prognoses are better compared to 18-59 year old RAHL patients, suggesting that eBPDac is a highly effective therapy for the treatment of Hodgkin lymphoma.


878 ASH denotes this abstract as clinically relevant

Sanjal H Desai, Michael A Spinner, Kevin A. David, et al.

Compared to conventional chemotherapy (CT), BV/Nivo achieves a higher CR rate and better PFS after ASCT. This combination can lead to durable remissions in patients with CR prior to ASCT. Although BBV had a higher response rate, survival after ASCT was similar to that of conventional CT. BV demonstrated lower response rates compared to CT. According to the authors, novel salvage therapies such as BV/Nivo and BBV may be preferable to conventional CT for R/R-cHL.


879 ASH denotes this abstract as clinically relevant

Julia Driessen, Fer de Wit, Alex F. Herrera, et al.

BV plus salvage chemotherapy followed by ASCT appears to increase PFS in relapsed cHL patients. However, this is not the case in primary refractory patients. It is reasonable to assume that other treatment modalities such as checkpoint inhibitors (CPI) should be considered in chemotherapy-resistant patients.
The authors suggest that the increase in OS after BV could be due to advances in treatment over time, since at the time of the studies in the chemo cohort, no novel therapies were available for patients who have failed ASCT.
The strong prognostic value of pre-ASCT-CMR for PFS is confirmed in this study. Prognostic factors for PFS and for achieving pre-ASCT-CMR are B symptoms, stage, and primary refractory disease.



Salim Kanoun, Alina Berriolo-Riedinger, Anne Ségolène Cottereau, et al.

At the start of the study, tumor burden (TMTV) and dissemination (SDmax) were assessed using the 18FDG-PET. These parameters enable the outcome of patients with advanced HL to be predicted. This is independent of an early response to treatment. In doing so, this parameters overcome the prognostic value of IPS and could be included in new prognostic scores. This would allow personalized therapy for advanced Hodgkin lymphoma.



Andrea C. Lo, Amy Liu, PhD, Qi Liu, M.Sc, et al.

Go to abstract to see the results.



Pietro R Di Ciaccio, Belinda Campbell, Kylie D Mason, et al.

Go to abstract to see the results.


  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos


Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.




Copyright 2024. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close